Asia-Pacific Erlotinib Hydrochloride Market Analysis 2012-2017 and Forecast 2018-2023

ReportPage
Report ID
26832
Published Date
16-Mar
No of Report Page
135
Report Category
Pharmaceuticals and Healthcare
Editor's Rating
US $6,600.00
US $6,600.00
US $3,300.00

  • Report Details

    Snapshot
    Erlotinib Hydrochloride is an anticancer drug from protein kinase inhibitors pharmacological group. This medication is used for the treatment of non-small cell lung cancer (NSCLC), locally advanced, unresectable or metastatic pancreatic cancer, and several other types of cancer. It is usually given after other cancer medicines have been tried without success. Erlotinib acts on the epiderm

    More...
  • Table Of Content

    Table of Content
    1 Industry Overview
    1.1 Erlotinib Hydrochloride Industry
    1.1.1 Overview
    1.1.2 Development of Erlotinib Hydrochloride
    1.2 Market Segment
    1.2.1 By Product Type
    1.2.2 By Application
    1.3 Asia-Pacific Overview
    2 Major Companies List
    2.1 Roche (Company Profile, Products & Services, Sales Data etc.)
    2.2 Cipla (Company Profile, Products

    More...
  • Inquiry Before Buying
    Inquiry Before Buying -
  • Request Sample
    Request For Sample